Tearsheet

NLS Pharmaceutics (NLSP)

Market Price (10/31/2025): $1.08 | Market Cap: $-
Sector: Health Care | Industry: Biotechnology

NLS Pharmaceutics (NLSP)

Market Price (10/31/2025): $1.08
Market Cap: $-
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0		Weak multi-year price returns 2Y Excs Rtn is -161%, 3Y Excs Rtn is -173%	Penny stock Mkt Price is 0.8
1			High stock price volatility Vol 12M is 124%

0	Weak multi-year price returns 2Y Excs Rtn is -161%, 3Y Excs Rtn is -173%
1	Penny stock Mkt Price is 0.8
2	High stock price volatility Vol 12M is 124%

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022
Share Price CYE	$1.08
Market Cap CYE ($ Bil)	0.0	-	-	-
Total Debt ($ Bil)	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.0	0.0
Enterprise Value ($ Bil)	0.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0
P/EBIT TTM	0.0	0.0	0.0	0.0
P/E TTM	0.0	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.0	3.0	2.8	2.7
P/EBIT TTM (Sector)	6.8	6.8	7.0	6.2
P/E TTM (Sector)	11.8	11.5	10.1	9.3

	10/31/25	2024	2023
Share Price CYE	$1.08
Market Cap CYE ($ Bil)	0.0	-	-
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.0	0.1	0.0
Enterprise Value ($ Bil)	0.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0
P/EBIT TTM	0.0	0.0	0.0
P/E TTM	0.0	0.0	0.0
Sector Ratios
P/S TTM (Sector)	3.0	3.0	2.8
P/EBIT TTM (Sector)	6.8	6.8	7.0
P/E TTM (Sector)	11.8	11.5	10.1

null

NLSP Stock

Return (1M):

null

Factor Drivers of Stock Movement

null

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
NLSP Return	-	-	16%	-54%	-91%	-64%	-97%
Peers Return	-15%	-9%	-6%	-3%	-3%	-16%	-43%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
NLSP Win Rate	-	18%	50%	50%	25%	44%
Peers Win Rate	18%	15%	23%	31%	22%	51%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
NLSP Max Drawdown	-	-	-69%	-75%	-92%	-38%
Peers Max Drawdown	-20%	-13%	-14%	-15%	-30%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique Key	Event	NLSP	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-94.5%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1728.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days

Compare to VRTX, APM, BBOT, GDTC, HIND

In The Past

NLS Pharmaceutics's stock fell -94.5% during the 2022 Inflation Shock from a high on 3/12/2021. A -94.5% loss requires a 1728.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About NLS Pharmaceutics (NLSP)

Business Description

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

	Best Bets In Health Care Sector
What You Pay
P/E	�	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	�	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	�	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	�	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	�	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	�	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Day 6 of Loss Streak for NLS Pharmaceutics Stock with -56% Return (vs. -65% YTD) [10/29/2025]	Notification

	Title
0	ARTICLES
1	Day 6 of Loss Streak for NLS Pharmaceutics Stock with -56% Return (vs. -65% YTD) [10/29/2025]

Trade Ideas

Select past ideas related to NLSP. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for NLS Pharmaceutics

Financials

	NLSP	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NLS Phar.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Price	0.76	419.89	1.47	12.00	2.15	5.58	3.87
Mkt Cap	-	107.8	-	-	-	-	107.8
Rev LTM	-	11,419	-	0	-	-	5,709
Op Inc LTM	-	-199	-	-93	-	-	-146
FCF LTM	-	3,500	-	-60	-	-	1,720
FCF 3Y Avg	-	1,984	-	-	-	-	1,984
CFO LTM	-	3,846	-	-60	-	-	1,893
CFO 3Y Avg	-	2,324	-	-	-	-	2,324

Growth & Margins

	NLSP	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NLS Phar.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Rev Chg LTM	-	10.5%	-	-	-	-	10.5%
Rev Chg 3Y Avg	-	11.0%	-	-	-	-	11.0%
Rev Chg Q	-	12.1%	-	-	-	-	12.1%
QoQ Delta Rev Chg LTM	-	2.9%	-	-	-	-	2.9%
Op Mgn LTM	-	-1.7%	-	-	-	-	-1.7%
Op Mgn 3Y Avg	-	26.5%	-	-	-	-	26.5%
QoQ Delta Op Mgn LTM	-	2.0%	-	-	-	-	2.0%
CFO/Rev LTM	-	33.7%	-	-	-	-	33.7%
CFO/Rev 3Y Avg	-	22.5%	-	-	-	-	22.5%
FCF/Rev LTM	-	30.6%	-	-	-	-	30.6%
FCF/Rev 3Y Avg	-	19.2%	-	-	-	-	19.2%

Valuation

	NLSP	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NLS Phar.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Cap	-	107.8	-	-	-	-	107.8
P/S	-	9.4	-	-	-	-	9.4
P/EBIT	-	24.5	-	-	-	-	24.5
P/E	-	29.6	-	-	-	-	29.6
P/CFO	-	28.0	-	-	-	-	28.0
Total Yield	-	3.4%	-	-	-	-	3.4%
Dividend Yield	-	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	2.1%	-	-	-	-	2.1%
D/E	-	0.0	-	-	-	-	0.0
Net D/E	-	-0.0	-	-	-	-	-0.0

Returns

	NLSP	VRTX	APM	BBOT	GDTC	HIND	Median
Name	NLS Phar.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
1M Rtn	-58.4%	7.2%	-27.2%	3.6%	8.0%	7.7%	5.4%
3M Rtn	-58.6%	-8.1%	-5.2%	-	14.4%	-	-6.6%
6M Rtn	-49.2%	-15.8%	59.8%	-	-6.5%	-	-11.2%
12M Rtn	-80.3%	-11.6%	5.0%	-	-3.4%	-	-7.5%
3Y Rtn	-96.4%	34.6%	-76.8%	-	-	-	-76.8%
1M Excs Rtn	-64.8%	2.2%	-34.2%	-1.9%	5.3%	-0.2%	-1.1%
3M Excs Rtn	-67.0%	-18.5%	-2.1%	-	8.1%	-	-10.3%
6M Excs Rtn	-70.9%	-37.6%	38.0%	-	-28.3%	-	-32.9%
12M Excs Rtn	-98.6%	-29.0%	-17.8%	-	-33.2%	-	-31.1%
3Y Excs Rtn	-173.0%	-41.0%	-151.9%	-	-	-	-151.9%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	0/0/-1	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	0/0/-1	5/16/2025	5/15/2024	5/5/2023	3/24/2022	5/14/2021	2/1/2021
Key Financials
Total Revenue	-	0	0	0	0	0	0
EBITDA	-	-2	-12	-16	-12	-3	-5
Operating Income	-	-4	-12	-15	-12	-2	-4
Net Income	-	-2	-12	-16	-12	-3	-5
EPS	-	-2.63	-12.75	-33.52	-40.00	-10.80	-18.50
Growth Rates
Total Revenue Growth	-	-	-	-	-	-	-
EBITDA Growth	-	84.8%	26.7%	-38.0%	-351.6%	43.2%	-13.9%
Operating Income Growth	-	69.2%	23.7%	-30.5%	-415.8%	45.2%	-21.7%
Net Income Growth	-	83.7%	26.2%	-38.1%	-317.5%	47.5%	-5.8%
Margins
EBITDA Margin	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-
Cash & Debt
Total Cash	�	2	1	9	5	0	0
Total Debt	0	0	2	0	0	2	1
Net Debt / (Cash)	�	-2	1	-9	-5	2	1
Cash Flows
Net Cash from Operations	-	-4	-10	-14	-15	-1	-0
Free Cash from Operations	-	-4	-10	-14	-15	-1	-0
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31
Period End
Filing Date
Key Financials Quarterly
Total Revenue
Ebitda
Operating Income
Net Income
EPS
Key Financials TTM
Total Revenue TTM
Ebitda TTM
Operating Income TTM
Net Income TTM
Growth Rates Quarterly
Total Revenue Growth
EBITDA Growth
Operating Income Growth
Net Income Growth
Margins Quarterly
EBITDA Margin
Operating Income Margin
Net Income Margin
Cash & Debt
Total Cash
Total Debt
Net Debt / (Cash)
Cash Flows Quarterly
FCF from Operations
Cash Flows TTM
FCF from Operations TTM
Returns to Shareholders Quarterly
Dividends
Share Repurchases
Return on Invested Capital (ROIC) Quarterly
ROIC
Return on Invested Capital (ROIC) TTM
ROIC TTM

	1M	2M	3M	6M	1Y	3Y
Beta	3.41	1.38	1.73	0.36	0.35	0.38
Up Beta	1.61	-1.43	0.05	-0.06	0.12	-0.48
Down Beta	3.86	1.81	3.62	0.10	-0.18	0.29
Up Capture	57%	159%	-11%	127%	24%	12%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	9	20	27	56	104	316
Down Capture	631%	251%	370%	123%	132%	108%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	11	21	34	62	135	413

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	95,155
Short Interest: % Change Since 9302025	-75.3%
Average Daily Volume	206,275
Days-to-Cover Short Interest	1

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	10062025	6-K 6/30/2025
12312024	5162025	20-F 12/31/2024
6302024	10182024	6-K 6/30/2024
12312023	5152024	20-F 12/31/2023
6302023	12062023	6-K 6/30/2023
12312022	5052023	20-F 12/31/2022
6302022	10112022	6-K 6/30/2022
12312021	3242022	20-F 12/31/2021
6302021	9282021	6-K 6/30/2021
12312020	5142021	20-F 12/31/2020
12312019	2012021	424B4 12/31/2019
12312018	2282020	F-1 12/31/2018

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

NLS Pharmaceutics (NLSP)

Market Price (10/31/2025): $1.08 | Market Cap: $-Sector: Health Care | Industry: Biotechnology

NLS Pharmaceutics (NLSP)

Market Price (10/31/2025): $1.08Market Cap: $-Sector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

NLSP Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About NLS Pharmaceutics (NLSP)

Interactive Breakdown

Better Bets than NLS Pharmaceutics (NLSP)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for NLS Pharmaceutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $1.08 | Market Cap: $-
Sector: Health Care | Industry: Biotechnology

Market Price (10/31/2025): $1.08
Market Cap: $-
Sector: Health Care
Industry: Biotechnology